Joseph Wu

Appearances

ETRASIMOD FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 2.5 YEARS OF POOLED SAFETY DATA FROM GLOBAL CLINICAL TRIALS
Date
May 9, 2023
BACKGROUND AND AIMS: A treat-to-target (TTT) strategy of striving for symptomatic and endoscopic remission is recommended for the management of inflammatory bowel diseases (IBD). Yet, real-world uptake of TTT strategies has been modest…
Presenter
Séverine Vermeire
Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven
Speakers
Laurent Peyrin-Biroulet
Julián Panés
Miguel Regueiro
Cleveland Clinic
Paulo Kotze
Aline Charabaty
Martina Goetsch
Kevin Shan
Joseph Wu
Aoibhinn McDonnell
John Woolcott
Silvio Danese
PREGNANCY OUTCOMES AFTER MATERNAL OR PATERNAL EXPOSURE IN THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAM
Date
May 20, 2024
BACKGROUND: Pregnant women with ulcerative colitis (UC) have a higher risk of adverse pregnancy outcomes vs age-matched controls.1 Tofacitinib is an oral Janus kinase inhibitor for the treatment of UC. There are no well-controlled studies on tofacitinib use in pregnant women…
Presenter
Uma Mahadevan
University of California san francisco
Speakers
María Chaparro
Michelle Segovia
Nicole Kulisek
Xiang Guo
Joseph Wu
Ivana Vranic
Annette Diehl
Marla Dubinsky
Icahn School of Medicine, Mount Sinai